Caribou Biosciences announced, on Monday, the appointment of Sundar Jagannath, MD, to its scientific advisory board. With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma, and he is the director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and professor of medicine, hematology and medical oncology, at Mount Sinai School of Medicine, New York.”We are honored to have Dr. Jagannath join our scientific advisory board. Dr. Jagannath is a distinguished oncologist who is renowned for his groundbreaking contributions to the field of multiple myeloma,” said Syed Rizvi, MD, Caribou’s chief medical officer. “Dr. Jagannath has a stellar reputation as a compassionate physician and researcher, whose guidance will be invaluable to Caribou as we advance the CaMMouflage Phase 1 trial for CB-011, our allogeneic anti-BCMA CAR-T cell therapy, for patients with relapsed or refractory multiple myeloma.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRBU:
- Caribou Biosciences appoints Sundar Jagannath to Scientific Advisory Board
- Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
- Caribou Biosciences to Participate in Upcoming Investor Conferences
- Caribou Biosciences initiated with an Outperform at Evercore ISI
- Caribou Biosciences announces FDA clearance of IND application for CB-012